ADGRL3 and glioblastoma: Therefore, we used The Cancer Genome Atlas (TCGA-GBM) dataset with the CL3 geneset and found that the CL3 signature was linked to poor GBM prognosis, specifically for progression-free interval (HR:13.7) and overall survival (HR = 21.8) (Fig. 3D, Supplementary Fig. 4E, F).